Researchers at the University of Barcelona found that combining pemafibrate and telmisartan significantly reduces liver fat and cardiovascular risks in MASLD models. The drug duo works better together than alone, likely due to complementary mechanisms. They also uncovered a new role for the PCK1 protein in fat metabolism.
Researchers at the University of Barcelona found that combining pemafibrate and telmisartan significantly reduces liver fat and cardiovascular risks in MASLD models. The drug duo works better together than alone, likely due to complementary mechanisms. They also uncovered a new role for the PCK1 protein in fat metabolism. Researchers at the University of Barcelona found that combining pemafibrate and telmisartan significantly reduces liver fat and cardiovascular risks in MASLD models. The drug duo works better together than alone, likely due to complementary mechanisms. They also uncovered a new role for the PCK1 protein in fat metabolism.